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Stomach Bugs and Diabetes:
An Astounding Observation
or Just Confounding?
The discovery that a Gram-negativespiral bacillus was responsible formost peptic ulcer disease (1) cre-
ated a paradigm shift that culminated in
Marshall and Warren being awarded the
Nobel Prize in Physiology or Medicine for
2005. Helicobacter pylori induces inﬂam-
mation that may be limited to the gastric
antrum, or can involve the corpus with
subsequent mucosal atrophy, and is char-
acterized, particularly in those strains
that are positive for cytotoxin-associated
gene A, by induction of cytokines includ-
ing interleukins (IL-) 1, 6, and 8, and
tumor necrosis factor-a (2). H. pylori is
an established risk factor for gastric ade-
nocarcinoma and lymphoma arising
from mucosa-associated lymphoid tissue
(MALT).
H. pylori appears to be acquired
mainly in childhood by the fecal-oral or
gastro-oral route. In developing countries,
80% ormore of the population are infected
by 20 years of age, while in the developed
world the prevalence of infection increases
with age. In each subsequent cohort, im-
proving socioeconomic conditions lead to
lower rates of infection in childhood (3). In
Australia, for example, seroprevalence was
recently estimated at;30% for those$70
years of age, but only 5% for those ,40
years of age (4).
Over the last 15–20 years, an increased
prevalence of diverse diseases, including
coronary artery (5) and cerebrovascular
(6) disease, Alzheimer disease, migraine,
Raynaud phenomenon, and chronic urti-
caria (7), has been reported in those with
evidence of H. pylori infection. Plausible
explanations to account for these associa-
tions include infection-induced systemic
inﬂammation with increased “oxidative
stress” and molecular mimicry (for exam-
ple, between H. pylori and endothelial
antigens) (7). However, many studies have
potentially been biased, particularly when
control groups were recruited opportu-
nistically, and it is not always clear that ap-
propriate adjustment has been made for
confounders like age and socioeconomic
status. For example, in relation to coronary
artery disease, when a socioeconomically
homogeneous sample such as from the
Physicians’ Health Study was examined,
no increased risk of future myocardial in-
farction was evident among those seropos-
itive for H. pylori (8). Currently, none of
these putative associations is widely ac-
cepted as causally linked (9).
In this month’s issue ofDiabetes Care,
Jeon et al. (10) report their analysis
of a Latino cohort from the Sacramento,
California, area. They followed 782 people
aged $60 years twice yearly for a decade;
participants were not known to have dia-
betes at entry and had serum assayed for
antibodies to H. pylori, herpes simplex
virus 1 (HSV-1), varicella zoster virus, cy-
tomegalovirus (CMV), and Toxoplasma
gondii, as well as inﬂammatory markers
(IL-6 and C-reactive protein [CRP]), lipids,
glucose, and insulin. During follow-up,
144 individuals developed diabetes (pre-
sumably type 2), with the rate being more
than double in those who were seroposi-
tive for H. pylori at entry compared with
the seronegative, even after adjusting for
age, sex, education, and covariates such as
smoking, BMI, blood pressure, and lipids.
In contrast, antibodies to the other infec-
tious agents were not associated with an
increased risk of developing diabetes, nor
wasH. pylori seropositivity associatedwith
higher concentrations of IL-6 or CRP. As
expected, the presence of insulin resistance
(evaluated by homeostasis model assess-
ment [HOMA-IR]) predicated subsequent
diabetes; however, HOMA-IR was not re-
lated to H. pylori status.
Simon at al. (11) were the ﬁrst to re-
port an association between H. pylori in-
fection and type 2 diabetes, and positive
reports have subsequently come from
groups in the Netherlands (12), Italy
(13), Turkey (14), and Africa (15). These
all have signiﬁcant methodological limita-
tions, including small sample sizes, case-
control designs, recruitment from clinical
populations, and potential for socio-
demographic confounding. Moreover,
other studies have been unable to substan-
tiate the association (16,17), while the larg-
est study (1,000 individuals from ethnically
diverse U.S. communities) (18) found that
an apparent higher prevalence of diabetes
in those seropositive for H. pylori, CMV,
hepatitis A, and HSV became nonsigniﬁ-
cant after adjustment for demographic
covariates.
The strength of the study of Jeon
et al. is its prospective nature. However,
the rate of seropositivity to H. pylori was
extraordinarily high (over 90%), so there
were few seronegative individuals; no
information is provided regarding the sen-
sitivity and speciﬁcity of the assay. Fur-
thermore, serology cannot distinguish
current from previous infection, and the
proportion of subjects previously given
eradication therapy is unknown. Residual
confounding (for example, by socioeco-
nomic factors) cannot be excluded, and
the mechanism by which H. pylori infec-
tion could predispose to diabetes remains
unclear, particularly as there were no
increases in the markers of systemic in-
ﬂammation that were examined. Several
reports have linked H. pylori infection
to insulin resistance (19,20), but the
HOMA-IR did not differ with H. pylori
status in the current study, and an asso-
ciation between H. pylori seropositivity
and insulin resistance is not supported by
analysis of data from the Third National
Health and Nutrition Examination Sur-
vey (NHANES III) (21). Jeon et al. suggest
that changes in gastric emptying could ad-
versely affect glycemia, but delayed gastric
emptying is a potential advantage, rather
than a disadvantage, in relation to glyce-
mic control in type 2 diabetic patients not
treated with insulin (22); moreover,
H. pylori has been shown not to affect
the rate of gastric emptying in patients
with diabetes (23). H. pylori-induced gas-
tritis can potentially affect the secretion of
“gastric” hormones including leptin and
ghrelin (24), which might feasibly predis-
pose to diabetes. Whether H. pylori could
induce a defect in insulin secretion re-
mains speculative. Type 2 diabetes would
seem highly unlikely to predispose to
H. pylori infection given the age at which
the latter is usually acquired.
It would be premature to advocate
an aggressive test-and-treat strategy for
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H. pylori in those at risk for developing
type 2 diabetes on the basis of the current
evidence. Demonstrating that such an in-
tervention would reduce the subsequent
incidence of diabetes would require a
very large, long-term prospective study
given that any effect is likely to be rela-
tively small. Universal attempts to eradi-
cate H. pylori carry concomitant risks of
drug-related morbidity and antibiotic re-
sistance, although it is likely that infection
rates will continue to decline in developing
countries as socioeconomic status im-
proves. Currently accepted indications to
test for H. pylori include active, or previ-
ous, peptic ulcer disease, gastric MALT
lymphoma, early gastric cancer, and “un-
investigated” dyspepsia (9); the latter ap-
plies to younger patients without “alarm
features” for malignancy. Diabetes is itself
associated with an increased prevalence
of gastrointestinal symptoms, including
dyspepsia (25), but the presence of symp-
toms in diabetes has not consistently been
shown to relate to H. pylori status (17).
Meta-analyses indicate a small, but statis-
tically signiﬁcant, beneﬁt in eradicating
H. pylori in nonulcer dyspepsia in the gen-
eral population (9), but there is insufﬁ-
cient evidence as to whether this applies
to patients with diabetes.
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